725237-35-4

Basic information

• Product Name: 4-amino-6-(3,5-dimethoxy-phenylamino)-2-methylsulfanyl-pyrimidine-5-carbonitrile
• Synonyms: 4-amino-6-(3,5-dimethoxy-phenylamino)-2-methylsulfanyl-pyrimidine-5-carbonitrile
• CAS NO: 725237-35-4
• Molecular Weight: 317.371
• Mol File: 725237-35-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-amino-6-(3,5-dimethoxy-phenylamino)-2-methylsulfanyl-pyrimidine-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-6-(3,5-dimethoxy-phenylamino)-2-methylsulfanyl-pyrimidine-5-carbonitrile(725237-35-4)
• EPA Substance Registry System: 4-amino-6-(3,5-dimethoxy-phenylamino)-2-methylsulfanyl-pyrimidine-5-carbonitrile(725237-35-4)

Safety Data

• Hazardous Substances Data: 725237-35-4(Hazardous Substances Data)

Upstream product

• 725237-21-8 4-chloro-6-(3,5-dimethoxy-phenylamino)-2-methylsulfanyl-pyrimidine-5-carbonitrile 
• 33097-13-1 4,6-dichloro-2-(methylthio)-5-pyrimidinecarbonitrile 
• 10272-07-8 3.5-dimethoxyaniline 

Downstream Products

• 725237-51-4 4-amino-6-(3,5-dimethoxy-phenylamino)-2-methylsulfanyl-pyrimidine-5-carboxylic acid amide 
• 725234-60-6 7-(3,5-dimethoxy-phenylamino)-5-methylsulfanyl-imidazo[1,2-c]pyrimidine-8-carboxylic acid amide 

Relevant articles and documents

KINASE INHIBITORS

Provided herein are kinase inhibiting compounds and methods of using the same.

Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors

Spleen tyrosine kinase (Syk) and zeta-associated protein kinase of 70 kDa (ZAP-70) are members of the Syk family and non-receptor-type protein tyrosine kinases, which play crucial roles in B- and T-cell activation. Therefore, a Syk family tyrosine kinases inhibitor would be a useful therapeutic agent for the treatment of various allergic disorders and autoimmune diseases. Previously, we reported that 1,2,4-triazolo[4,3-c]pyrimidine derivative 1 and 1,2,4-triazolo[1,5-c]pyrimidine derivative 2 showed strong inhibitory activities against Syk family kinases. These compounds also exhibited high-level suppression of IL-2 in cellular assays. However, their oral efficacies were poor in a mouse model of IL-2 production. To improve oral effectiveness, we investigated a new series of Syk family kinases inhibitors. We found that imidazo[1,2-c]pyrimidine derivatives potently inhibited the Syk family kinases. Among these agents, compound 9f not only showed strong inhibitory activities against Syk and ZAP-70 kinases in vitro, but its oral administration resulted in the in vivo suppression of both the passive cutaneous anaphylaxis reaction and Concanavalin A-induced IL-2 production in a mouse model.